The Light for PD trial was a fully remote, randomized, double-blind, sham-controlled trial evaluating Celeste in individuals living with Parkinson's disease. The trial enrolled 351 participants across the United States. With all participant activity now complete, the company will proceed with database lock and final data analysis.

PhotoPharmics will present topline results from the Light for PD trial to healthcare professionals at the World Parkinson Congress (WPC), taking place May 25–27, 2026, in Phoenix. The presentation is scheduled for May 26 at 7:45 AM in Room 224. The company will also exhibit at Booth #520 throughout the congress.

The post PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress appeared first on PhotoPharmics.

The company's participation coincides with the final weeks of its pivotal Phase 3 Light for PD clinical trial — a fully remote, randomized, double-blind, placebo-controlled study evaluating Celeste®, an investigational photo-neuromodulation device, in individuals living with Parkinson's disease. Topline results are anticipated to be shared at the World Parkinson Congress in late May 2026.

The post PhotoPharmics to Participate in AAN Annual Meeting as Phase 3 Light for PD Trial Nears Completion appeared first on PhotoPharmics.

The publication marks an important scientific milestone for the Company and contributes to the growing body of clinical evidence examining circadian-effective photo-neuromodulation in PD. The Phase 2 findings informed the design of the Company’s ongoing Phase 3/Pivotal trial, which is fully enrolled and expected to complete in Q2 2026.

The Phase 2 study evaluated daily photo-neuromodulation delivered via a patented spectral band of light frequencies designed to engage circadian pathways.  The trial assessed both motor and non-motor features in individuals with PD receiving standard-of-care therapies. Celeste was well tolerated over the six-month period, with no serious adverse events reported.

The post PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial appeared first on PhotoPharmics.

The post Understanding Parkinson’s Fatigue appeared first on PhotoPharmics.

The post The Role of Nutrition in Parkinson’s Disease appeared first on PhotoPharmics.

“Exceeding our target and closing enrollment is a remarkable milestone for the Parkinson’s community,” said Kent Savage, Chief Executive Officer of PhotoPharmics. “We’re proving that rigorous science can be both patient-centered and home-based. We’re deeply grateful to our investigators, study teams, and especially our participants and their families, whose courage and commitment make this work possible.”

The post PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial appeared first on PhotoPharmics.

The post Young-Onset Parkinson’s: Navigating Your Journey After an Early Diagnosis appeared first on PhotoPharmics.

The post PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress appeared first on PhotoPharmics.

The post Understanding and Managing Depression and Anxiety in Parkinson’s appeared first on PhotoPharmics.